Alliance A041702

A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL)

Objective

This phase III trial compares adding a new anti-cancer drug (venetoclax) to the usual treatment (ibrutinib plus obinutuzumab) in older patients with chronic lymphocytic leukemia who have not received previous treatment.

NCT#03737981

Clinical Trial Categories

• Lymphoma/Lymph Node/Leukemia/Blood-related Cancers

Contact

NH Oncology Hematology Clinical Research Dept. at (603) 224-2556